Fort Point Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Fort Point Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-21,500	Closed	-$255K	–	147
2017 Q2	$255K	Hold	21,500	–	–	0.14%	77
2017 Q1	$318K	Buy	21,500 +8,000	+59%	+$130K	0.16%	73
2016 Q4	$222K	Hold	13,500	–	–	0.12%	92
2016 Q3	$245K	Buy	+13,500	New	+$264K	0.11%	115

Other funds holding HZNP

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fort Point Capital Partners's HZNP Position: Q3 2017 in Review

Fort Point Capital Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2017, closing a stake of 21,500 shares — an estimated $255K sold.

Fort Point Capital Partners first reported a position in HZNP in Q3 2016 and held it in 4 quarters. The position peaked at $318K in Q1 2017. 181 funds tracked by Wall St. Rank hold HZNP as of Q3 2017.

Fort Point Capital Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2017 after selling out during the quarter.
Fort Point Capital Partners sold 21,500 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2017, an estimated $255K.
Fort Point Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 4 quarters.
Fort Point Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $318K in Q1 2017.
181 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2017.

Based on Fort Point Capital Partners's 13F filing for Q3 2017, filed 14 Nov 2017.